Recommendation ID
NG191/15
Question

What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2 variants?

Any explanatory notes
(if applicable)

Suggested PICO (Population, Intervention, Comparator, Outcome)

P: people being treated for acute COVID-19 disease and who are not hospitalised with COVID-19

Subgroups of particular interest:

  • ethnicity
  • children and young people
  • pregnant women
  • vaccination status
  • people with comorbidities
  • people who are immunocompromised

I: neutralising monoclonal antibodies

  • combination of casirivimab and imdevimab
  • sotrovimab
  • any neutralising monoclonal antibodies that are granted marketing authorisation in the future

C:

  • standard care
  • other neutralising monoclonal antibodies

O:

  • health-related quality of life
  • adverse events
  • progression to invasive mechanical ventilation
  • progression to non-invasive respiratory support
  • hospitalisation and duration of hospitalisation
  • mortality

Source guidance details

Comes from guidance
COVID-19 rapid guideline: managing COVID-19
Number
NG191
Date issued
March 2021

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 26/01/2022